Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors.

Abstract

INTRODUCTION:

Stereotactic ablative radiotherapy (SABR) is highly effective at controlling early stage primary lung cancer and lung metastases. Although previous studies have suggested that treating multiple lung tumors with SABR is safe, post-treatment changes in respiratory function have not been analyzed in detail.

PATIENTS AND METHODS:

We retrospectively identified patients with 2 or more primary lung cancers or lung metastases treated with SABR and analyzed clinical outcomes and predictors of toxicity. We defined a composite respiratory decline endpoint to include increased oxygen requirement, increased dyspnea scale, or death from respiratory failure not owing to disease progression.

RESULTS:

A total of 86 patients treated with SABR to 203 lung tumors were analyzed. A total of 21.8% and 41.8% of patients developed composite respiratory decline at 2 and 4 years, respectively. When accounting for intrathoracic disease progression, 12.7% of patients developed composite respiratory decline at 2 years. Of the patients, 7.9% experienced grade 2 or greater radiation pneumonitis. No patient- or treatment-related factor predicted development of respiratory decline. The median overall survival was 46.9 months, and the median progression-free survival was 14.8 months. The cumulative incidence of local failure was 9.7% at 2 years.

CONCLUSION:

Although our results confirm that SABR is an effective treatment modality for patients with multiple lung tumors, we observed a high rate of respiratory decline after treatment, which may be owing to a combination of treatment and disease effects. Future studies may help to determine ways to avoid pulmonary toxicity from SABR.

• Authors: Everett J Moding, Rachel Liang, Frederick M Lartey, Peter G Maxim, Arthur Sung, Maximilian Diehn, Billy W Loo Jr, Michael F Gensheimer
• Journal: Clinical lung cancer (Clin Lung Cancer) Vol. 20 Issue 6 Pg. 461-468.e2 (11 2019) ISSN: 1938-0690 [Electronic] United States
• PMID: 31377143 (Publication Type: Journal Article)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Topics

• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Non-Small-Cell Lung (diagnosis, radiotherapy)
• Dose Fractionation, Radiation
• Female
• Follow-Up Studies
• Humans
• Lung Neoplasms (diagnosis, radiotherapy)
• Male
• Middle Aged
• Neoplasm Metastasis
• Prognosis
• Radiation Injuries (diagnosis)
• Radiofrequency Ablation (methods)
• Radiosurgery (methods)
• Respiratory Insufficiency (diagnosis, etiology)
• Retrospective Studies
• Survival Analysis
• Young Adult